Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck
An Open-label Phase 2 Study of Dalantercept in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Listed as NCT01458392, this PHASE2 trial focuses on Squamous Cell Carcinoma of the Head and Neck and remains completed. Sponsored by Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA, it has been updated 11 times since 2011, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jun 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Nov 2022 — Jun 2023 [monthly]
Completed PHASE2
-
Oct 2022 — Nov 2022 [monthly]
Completed PHASE2
▶ Show 6 earlier versions
-
Oct 2021 — Oct 2022 [monthly]
Completed PHASE2
-
Jan 2021 — Oct 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Aug 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Feb 2017 — Aug 2017 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Oct 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
For direct contact, visit the study record on ClinicalTrials.gov .